IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
A phase 3 trial of IBI363, Bevacizumab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
Overview
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer is a phase 3 interventional study registered as NCT07722494 by Innovent Biologics (Suzhou) Co. Ltd., with 550 participants planned, started 2026-07-31 and due to reach its primary completion in 2028-10-31. Interventions recorded: IBI363 + bevacizumab, Investigator's choice of therapy. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of IBI363 in Subjects With Advanced Melanoma
Shares IBI363, Innovent Biologics.
- TrialA Study of IBI363 in Subjects with Advanced Solid Malignancies
Shares IBI363, Innovent Biologics, Colorectal cancer.
- TrialA Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat
Shares IBI363, Innovent Biologics.
- TrialIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small
Shares IBI363, Innovent Biologics.
- TrialStudy of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Shares Bevacizumab, Colorectal cancer.
- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Bevacizumab, Colorectal cancer.
- TrialAK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Shares Bevacizumab, Colorectal cancer.
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3
Shares Bevacizumab, Colorectal cancer.